JP6817073B2 - セロトニン受容体を標的にする化合物および方法 - Google Patents

セロトニン受容体を標的にする化合物および方法 Download PDF

Info

Publication number
JP6817073B2
JP6817073B2 JP2016568912A JP2016568912A JP6817073B2 JP 6817073 B2 JP6817073 B2 JP 6817073B2 JP 2016568912 A JP2016568912 A JP 2016568912A JP 2016568912 A JP2016568912 A JP 2016568912A JP 6817073 B2 JP6817073 B2 JP 6817073B2
Authority
JP
Japan
Prior art keywords
compound
receptors
receptor
less
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016568912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521367A (ja
JP2017521367A5 (https=
Inventor
ブース，レイモンド，ジー．
Original Assignee
ノースイースタン ユニバーシティ
ノースイースタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースイースタン ユニバーシティ, ノースイースタン ユニバーシティ filed Critical ノースイースタン ユニバーシティ
Publication of JP2017521367A publication Critical patent/JP2017521367A/ja
Publication of JP2017521367A5 publication Critical patent/JP2017521367A5/ja
Application granted granted Critical
Publication of JP6817073B2 publication Critical patent/JP6817073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016568912A 2014-05-19 2015-05-19 セロトニン受容体を標的にする化合物および方法 Active JP6817073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000286P 2014-05-19 2014-05-19
US62/000,286 2014-05-19
PCT/US2015/031523 WO2015179366A1 (en) 2014-05-19 2015-05-19 Serotonin receptor-targeting compounds and methods

Publications (3)

Publication Number Publication Date
JP2017521367A JP2017521367A (ja) 2017-08-03
JP2017521367A5 JP2017521367A5 (https=) 2018-06-28
JP6817073B2 true JP6817073B2 (ja) 2021-01-20

Family

ID=54554616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568912A Active JP6817073B2 (ja) 2014-05-19 2015-05-19 セロトニン受容体を標的にする化合物および方法

Country Status (7)

Country Link
US (1) US11021435B2 (https=)
EP (1) EP3145906B1 (https=)
JP (1) JP6817073B2 (https=)
CN (1) CN106573872B (https=)
BR (1) BR112016027096B1 (https=)
ES (1) ES2967976T3 (https=)
WO (1) WO2015179366A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024745A2 (pt) * 2015-05-19 2018-11-13 Univ Northeastern compostos e métodos para modulação de receptores de serotonina na periferia.
CN108794308B (zh) * 2017-04-27 2021-07-20 北京大学深圳研究生院 1,2,3,4-四氢萘类化合物及其制备方法和应用
FI4048249T3 (fi) * 2019-10-23 2025-12-05 Maplight Therapeutics Inc Menetelmiä autismikirjon häiriön oireiden hoitamiseksi
AU2021329920A1 (en) * 2020-08-19 2023-04-27 Northeastern University Serotonin receptor modulators
US20240327353A1 (en) * 2021-07-14 2024-10-03 Northeastern University Serotonin 5-HT2A, 5-HT2B, and 5-HT2C Receptor Inverse Agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9509156D0 (en) * 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
EP0770397B1 (en) 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
US20030008880A1 (en) * 2001-05-02 2003-01-09 Pfizer Inc. 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
EP1956006A1 (en) * 2007-02-06 2008-08-13 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments
US20100227934A1 (en) 2007-06-15 2010-09-09 University Of Florida Research Foundation, Inc Therapeutic compounds and methods of use
JP5513378B2 (ja) 2007-06-15 2014-06-04 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
JP5932636B2 (ja) 2009-05-05 2016-06-08 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 治療化合物

Also Published As

Publication number Publication date
EP3145906A4 (en) 2018-01-24
US20170081273A1 (en) 2017-03-23
CN106573872B (zh) 2021-07-20
CN106573872A (zh) 2017-04-19
US11021435B2 (en) 2021-06-01
BR112016027096B1 (pt) 2023-04-11
BR112016027096A2 (pt) 2018-07-10
EP3145906A1 (en) 2017-03-29
JP2017521367A (ja) 2017-08-03
WO2015179366A1 (en) 2015-11-26
EP3145906B1 (en) 2023-10-04
ES2967976T3 (es) 2024-05-06

Similar Documents

Publication Publication Date Title
JP6817073B2 (ja) セロトニン受容体を標的にする化合物および方法
US11111210B2 (en) Phenyl cyclohexanone derivatives and methods of making and using them
IL298769A (en) Benzofuran compounds are useful for mental disorders or mental enhancement
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
HUE030081T2 (en) Heterocyclic benzodioxole or benzodioxepine compounds as phosphodiesterase inhibitors
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
WO2007069565A1 (ja) 二環式複素環化合物
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
MX2015003637A (es) Piridinonas biciclicas novedosas.
AU2019216492A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
CN117642379A (zh) 苯烷基胺及其制备和使用方法
TW202517609A (zh) 氘化有機化合物及其用途(二)
JP2023530715A (ja) アリールスルホニル誘導体及びムスカリン性アセチルコリン受容体ｍ５阻害剤としてのその使用
TW200808784A (en) Substituted phenyl methanone derivatives
Oberdorf et al. Thiophene bioisosteres of spirocyclic σ receptor ligands: Relationships between substitution pattern and σ receptor affinity
Banister et al. 7-Azabicyclo [2.2. 1] heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands
US20240067611A1 (en) Phenyl cyclohexanone derivatives and methods of making and using them
CN121335888A (zh) (s)-噻萘普汀和在治疗与过氧化物酶体增殖物激活受体相关的障碍和病症中的用途
WO2023107653A2 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
CN118510544A (zh) 大麻素类的磷酸酯前药
HK1236024A1 (en) Serotonin receptor-targeting compounds
HK1236024B (en) Serotonin receptor-targeting compounds
RS67052B1 (sr) Vmat2 inhibitori i postupci primene
ES2892175T3 (es) Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central
US11827606B2 (en) Phenyl cyclohexanone derivatives and methods of making and using them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201224

R150 Certificate of patent or registration of utility model

Ref document number: 6817073

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250